By Adriano Marchese
ANI Pharmaceuticals shares rose Friday morning after the company reported better-than-expected results in the fourth quarter and raised its guidance for the current year.
Shares traded over 10% higher at $60.08.
The specialty pharmaceutical company raised its revenue projections to a range of $756 million to $776 million for 2025, up from a previous guidance of $739 million to $759 million.
Adjusted earnings before interest, taxes, depreciation and amortization have also been revised higher to a range of $190 million to $200 million. Previously, the company expected $182 million to $192 million.
ANI also set its guidance for adjusted earnings per share of $6.12 to $6.49.
In its final quarter, total revenue rose to $190.6 million from $131.7 million, topping expectations of a more modest rise to $175.4 million, according to FactSet.
ANI swung to a loss of $10.3 million from a profit of $1.2 million. On a per-share basis, this was a loss of 55 cents, compared with a gain of 4 cents a year earlier.
Adjusted earnings, which strips out exceptional costs and one-off items, came to $1.63 a share, beating expectations of $1.44 a share.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 28, 2025 09:44 ET (14:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。